One patient in the solithromycin group experienced a grade 3 elevation in the liver enzyme ALT but the patient also had hepatitis C and entered the study with ALT enzymes already moderately elevated. In addition, there were two cases of temporary elevations of AST in the solithromycin group but neither had concomitant increase in bilirubin -- a more serious signal of liver toxicity....What ever...talking it down doesn't change the obvious.
This was well controlled hand picked group of patient's and there was still liver toxicity...Just wait until it hits general population when approved, Ketek looked ok in clinical trials too. Then this Liver hand grenade was thrown into the general population and people died. Just give me Tedizolid thank you.